ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 361

Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA

Anthony Marotta1, Dirkjan van Schaardenburg2, Gilles Boire3, Désirée van der Heijde4, Robert Landewé5, Maarten Boers6, C.F. Allaart7, Mairead Murphy8, Samina Turk9, Vivian P. Bykerk10, Edward Keystone11, Katherine A. Siminovitch11 and Walter P. Maksymowych12, 11423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, 2Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 3Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 4Leiden University Medical Center, Leiden, Netherlands, 5Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 6Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, 7Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8Augurex Life Sciences Corp., North Vancouver, BC, Canada, 9Reade, Amsterdam, Netherlands, 10Divison of Rheumatology, Hospital for Special Surgery, New York, NY, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Department of Medicine, University of Alberta, Edmonton, AB, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, citrullination, complimentary and diagnosis, Early Rheumatoid Arthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the ACPA titer without determining whether the observed reactivity is specific for the citrullinated or arginilated form of the peptide. Brink showed that autoantibodies (AAb) directed to uncitrullinated peptides may occur prior to the development of cit specific antibodies. Consequently, important information related to citrullination and its relationship to clinical outcomes might be overlooked. 14-3-3η is normally an intracellular protein whose extracellular expression in RA leads to the development of specific pan-reactive AAb to the native protein that inform joint damage prognosis, and also cit-14-3-3η-reactive AAbs. In this study we examined 14-3-3η cit:arg reactivity and its complementarity to ACPA in diagnosing RA.

Methods A total of 623 subjects were evaluated; 190 DMARD-naïve early RA patients (READE n=139, Sherbrooke n=40, iCOBRA n=11), 115 with classified established RA (n=65 from the RAPPORT cohort; 50 from the year 3 time point of the BeSt study). 318 controls constituted 106 healthy and 212 disease controls with connective tissue disease, OA, AS and autoimmune conditions. AAb levels were measured using the MSD ECL platform. Seven (7) cit/arg sites on 14-3-3η were examined for differential AAb reactivity between RA and controls using the Kruskal-Wallis test and ROC curve analysis.  The paired t-test was used to determine differences in cit:arg reactivity. Anti-cit-14-3-3η positivity at an individual cit site was defined by a 50% increase in reactivity to the cit site over the corresponding arg site, with overall anti-cit positivity defined as positive at a least one cit site.

Results The significantly higher reactivity of anti-cit 14-3-3η in RA versus controls, based on ROC analysis and assessment of cit:arg fold reactivity, resulted in the prioritization of 4 cit sites (1, 2, 4, 7) which reside on the protein surface. Reactivity was not confined to the cit form of the peptide since significantly higher reactivity to the arg peptide was also apparent in RA versus controls. Importantly, 50% of early and 54% of established RA patients were anti-cit-14-3-3η positive. While the Fisher Exact test revealed a significant association between anti-cit-14-3-3η and ACPA positivity (LR = 19.1 p<0.0001), in ACPA negatives, 25% of early and 41% of established RA patients were positive for anti-cit-14-3-3η. Combining ACPA and anti-cit-14-3-3η reactivity improved the early RA capture rate (table).

 

Early RA (n=190)

Established RA (n=115)

Based on ACPA

ACPA -ve (n=60)

ACPA +ve (n=130)

ACPA -ve (n=27)

ACPA +ve (n=88)

Cit-14-3-3η eta Ab, % (n)

25% (15)

62% (80)

41% (11)

58% (51)

Combination of Markers

 

ACPA

68% (130)

77% (88)

Cit-14-3-3η

50% (95)

54% (62)

Either Marker

76% (145)

86% (99)

Conclusion In RA, AAbs exist against 14-3-3η native and citrullinated protein. Anti cit-14-3-3η AAbs are expressed in early and established RA and complement ACPA as a diagnostic aid.  Relative cit:arg AAb reactivity should be accounted for in citrullination assays to properly assess the burden of citrullination in RA.

Ref. Brink M et al. ARD. 2014 Jul;73(7):e46.


Disclosure:

A. Marotta,

Augurex Life Sciences Corp.,

3;

D. van Schaardenburg,

Augurex Life Sciences Corp,

5;

G. Boire,

Augurex Life Sciences Corp,

5;

D. van der Heijde,

Augurex Life Sciences Corp,

5;

R. Landewé,

Augurex Life Sciences Corp,

5;

M. Boers,

Augurex Life Sciences Corp,

5;

C. F. Allaart,

Augurex Life Sciences Corp,

5;

M. Murphy,

Augurex Life Sciences Corp,

3;

S. Turk,
None;

V. P. Bykerk,

Augurex Life Sciences Corp,

5;

E. Keystone,

Augurex Life Sciences Corp,

5;

K. A. Siminovitch,
None;

W. P. Maksymowych,

Augurex Life Sciences Corp,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrullinated-14-3-3%ce%b7-antibodies-are-specific-for-early-and-established-ra-and-are-complementary-to-acpa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences